Chong Wang, Qiang Wang, Huimin Wang, Zheng Li, Jitang Chen, Zhijie Zhang, Haowen Zeng, Ximiao Yu, Xiaoquan Yang, Xiangliang Yang, Zifu Li
Small molecular prodrug-based nanomedicines with high drug-loading efficiency and tumor selectivity have attracted great attention for cancer therapy against solid tumors, including triple negative breast cancers (TNBC). However, abnormal tumor mechanical microenvironment (TMME) severely restricts antitumor efficacy of prodrug nanomedicines by limiting drug delivery and fostering cancer stem cells (CSCs). Herein, we employed carbamate disulfide bridged doxorubicin dimeric prodrug as pharmaceutical ingredient, marketed IR780 iodide as photothermal agent, and biocompatible hydroxyethyl starch-folic acid conjugate as amphiphilic surfactant to prepare a theranostic nanomedicine (FDINs), which could actively target at TNBC 4 T1 tumor tissues and achieve reduction-responsive drug release with high glutathione concentration in cancer cells and CSCs...
December 3, 2022: Journal of Controlled Release